



00-000000000



201950

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

**Patient Name:** \_\_\_\_\_ **Date:** 10/11/2024  
**Patient ID:** \_\_\_\_\_ **Patient Date Of Birth:** \_\_\_\_\_  
**Patient Group No:** \_\_\_\_\_ **Patient Phone:** \_\_\_\_\_ **Physician Name:** \_\_\_\_\_  
**NPI#:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_  
**Physician Office Telephone:** \_\_\_\_\_  
**Physician Office Address:** \_\_\_\_\_  
**Drug Name (specify drug):** \_\_\_\_\_  
**Quantity:** \_\_\_\_\_ **Frequency:** \_\_\_\_\_ **Strength:** \_\_\_\_\_  
**Route of Administration:** \_\_\_\_\_ **Expected Length of Therapy:** \_\_\_\_\_  
**Diagnosis:** \_\_\_\_\_ **ICD Code:** \_\_\_\_\_  
**Comments:** \_\_\_\_\_

**Please check the appropriate answer for each applicable question.**

1. What is the patient's diagnosis?
  - Cholangiocarcinoma (If checked, go to 2) ☐
  - Myeloid/lymphoid neoplasms (If checked, go to 2) ☐
  - Other, please specify. (If checked, no further questions) ☐
2. Is the patient currently receiving treatment with the requested medication? **Y** ☐ **N** ☐
3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen? **Y** ☐ **N** ☐
4. What is the patient's diagnosis?
  - Cholangiocarcinoma (If checked, go to 5) ☐
  - Myeloid/lymphoid neoplasms (If checked, go to 9) ☐
5. What is the clinical setting in which the requested medication will be used?
  - Metastatic disease (If checked, go to 6) ☐
  - Progressive disease (If checked, go to 6) ☐
  - Resected gross residual (R2) disease (If checked, go to 6) ☐
  - Unresectable disease (If checked, go to 6) ☐
  - Other, please specify. (If checked, no further questions) ☐
6. What is the place in therapy in which the requested drug will be used?
  - First line treatment (If checked, no further questions) ☐
  - Subsequent treatment (If checked, go to 7) ☐
7. Does the patient's cancer have a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement? **ACTION REQUIRED:** If Yes, attach chart note(s) or test results of fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement.

Yes (If checked, go to 8)

☐

No (If checked, no further questions)

☐

Unknown (If checked, no further questions)

☐

ACTION REQUIRED: Submit supporting documentation

8. Will the requested medication be used as a single agent?

Y

☐

N

☐

9. Does the disease have a fibroblast growth factor receptor 1 (FGFR1) rearrangement?

ACTION REQUIRED: If Yes, attach chart note(s) or test results of fibroblast growth factor receptor 1 (FGFR1) rearrangement.

Yes (If checked, no further questions)

☐

No (If checked, no further questions)

☐

Unknown (If checked, no further questions)

☐

ACTION REQUIRED: Submit supporting documentation

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

---

**Prescriber (Or Authorized) Signature and Date**

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to [www.caremark.com/epa](http://www.caremark.com/epa).